ASX Announcement 20 October 2026 Q1 FY27 Quarterly Activities Report & Appendix 4C Record core testing revenue, up 31% vs PCP; GI Navigator launched in Australia and the United Kingdom; cost base reset underway. Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a...
Q1 FY27 Quarterly Activities Report & Appendix 4C
Filed with ASX · · 11 pages · English
Summary by 6ix AI
Additionally, the company has implemented significant cost reductions and plans further measures to optimize its financial position. The report also discusses the company's cash flow situation, including a net operating cash outflow and plans for a capital raise through a placement.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Microba Life Sciences Limited on 6ix
Story so far
Earlier from Microba Life Sciences
- Microba secures $2m placement and increases cost reductions
- Date of AGM and closing date for Director Nominations
- Notification of cessation of securities - MAP
- Microba launches GI Navigator in Australia and the UK
- Change in substantial holding
Later from Microba Life Sciences
- Proposed issue of securities - MAP
- Update on Commercial Terms for Proposed Merger with MAP
- Final Director's Interest Notice - Gene Tyson
- Final Director's Interest Notice - Ian Frazer
- Letter to Shareholders, Notice of AGM & Proxy Form
Follow Microba Life Sciences into a list and get an email when it puts out news.
Follow Microba Life Sciences